177 related articles for article (PubMed ID: 30801881)
1. Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.
Latham NH; Pedrana A; Doyle JS; Howell J; Williams B; Higgs P; Thompson AJ; Hellard ME
J Viral Hepat; 2019 Jul; 26(7):919-922. PubMed ID: 30801881
[TBL] [Abstract][Full Text] [Related]
2. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
[TBL] [Abstract][Full Text] [Related]
3. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
Williams B; Howell J; Doyle J; Thompson AJ; Draper B; Layton C; Latham N; Bramwell F; Membrey D; Mcpherson M; Roney J; Stoové M; Hellard ME; Pedrana A
Int J Drug Policy; 2019 Oct; 72():91-98. PubMed ID: 31129023
[TBL] [Abstract][Full Text] [Related]
4. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
MacIsaac MB; Whitton B; Anderson J; Cogger S; Vella-Horne D; Penn M; Weeks A; Elmore K; Pemberton D; Winter RJ; Papaluca T; Howell J; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Clark N; Holmes JA; Thompson AJ
Int J Drug Policy; 2024 Mar; 125():104317. PubMed ID: 38281385
[TBL] [Abstract][Full Text] [Related]
5. Point-of-care rapid testing for hepatitis C antibodies at New Zealand needle exchanges.
Noller G; Bourke J
N Z Med J; 2020 Nov; 133(1525):84-95. PubMed ID: 33223551
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study.
Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore GJ; Applegate TL;
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):514-520. PubMed ID: 28442271
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
Kåberg M; Hammarberg A; Lidman C; Weiland O
Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
[TBL] [Abstract][Full Text] [Related]
8. The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
Howell J; Traeger MW; Williams B; Layton C; Doyle JS; Latham N; Draper B; Bramwell F; Membrey D; McPherson M; Roney J; Stoové M; Thompson AJ; Hellard ME; Pedrana A
J Viral Hepat; 2022 May; 29(5):375-384. PubMed ID: 35274403
[TBL] [Abstract][Full Text] [Related]
9. Using an intersectionality lens to explore barriers and enablers to hepatitis C point-of-care testing: a qualitative study among people who inject drugs and service providers.
Fontaine G; Presseau J; Bruneau J; Etherington C; Thomas IM; Hung JC; van Allen Z; Patey AM; Kareem A; Mortazhejri S; Høj SB; Boyer-Legault G; Grimshaw JM
Int J Equity Health; 2024 Jun; 23(1):124. PubMed ID: 38886803
[TBL] [Abstract][Full Text] [Related]
10. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
[TBL] [Abstract][Full Text] [Related]
11. Values and preferences for hepatitis C self-testing among people who inject drugs in Kyrgyzstan.
Martínez-Pérez GZ; Nikitin DS; Bessonova A; Fajardo E; Bessonov S; Shilton S
BMC Infect Dis; 2021 Jun; 21(1):609. PubMed ID: 34171990
[TBL] [Abstract][Full Text] [Related]
12. Engaging people who inject drugs in hepatitis C virus testing and prevention through community-based outreach, in Sydney, Australia.
Coupland H; White B; Bates A; Park JN; Iversen J; Maher L
Drug Alcohol Rev; 2019 Feb; 38(2):177-184. PubMed ID: 30652363
[TBL] [Abstract][Full Text] [Related]
13. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
[TBL] [Abstract][Full Text] [Related]
14. Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015.
Graham S; Maher L; Wand H; Doyle M; Iversen J
Int J Drug Policy; 2017 Sep; 47():69-76. PubMed ID: 28735774
[TBL] [Abstract][Full Text] [Related]
15. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study.
Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J;
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891535
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain.
Saludes V; Antuori A; Lazarus JV; Folch C; González-Gómez S; González N; Ibáñez N; Colom J; Matas L; Casabona J; Martró E
Int J Drug Policy; 2020 Jun; 80():102734. PubMed ID: 32470849
[TBL] [Abstract][Full Text] [Related]
17. Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014.
Blackburn NA; Patel RC; Zibbell JE
Public Health Rep; 2016; 131 Suppl 2(Suppl 2):91-7. PubMed ID: 27168667
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia.
Butler K; Day C; Sutherland R; van Buskirk J; Breen C; Burns L; Larney S
Int J Drug Policy; 2017 Sep; 47():102-106. PubMed ID: 28789820
[TBL] [Abstract][Full Text] [Related]
19. A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa.
Saayman E; Hechter V; Kayuni N; Sonderup MW
Harm Reduct J; 2023 Mar; 20(1):27. PubMed ID: 36870990
[TBL] [Abstract][Full Text] [Related]
20. Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia.
Handanagic S; Sevic S; Barbaric J; Dominkovic Z; Dakovic Rode O; Begovac J; Bozicevic I
Drug Alcohol Depend; 2017 Feb; 171():132-139. PubMed ID: 28088084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
